Fluge & Mella's pre-trial study highlights life-changing potential of rituximab
Sasha gives the background and Simon gives the interpretation of the latest study from Haukeland, published today...
Discuss the article on the Forums.

Latent population, 3.7% or twice that?

Discussion in 'XMRV Testing, Treatment and Transmission' started by FernRhizome, Dec 28, 2009.

  1. FernRhizome

    FernRhizome Senior Member

    Messages:
    412
    Likes:
    0
    Hi folks:
    I am wondering if the percent of XMRV is closer to double the 3.7% reported in the Science paper. I am wondering about this because after WPI refined it's test methods it findings in CFS jumped from 67% to nearly 95 to 99%. If they went back and retested the controls wouldn't that figure also almost double? I wonder when refined testing information on healthy controls will be published? ~FernRhizome
     
  2. FernRhizome

    FernRhizome Senior Member

    Messages:
    412
    Likes:
    0
    Hi:
    That's interesting. I've also been wondering why WPI didn't immediately post their government grant as well as it's been more than a month since it was public knowledge. There must be grant money going into the WPI/Cornell/Columbia research study, but wonder why that one isn't on their site yet? Perhaps it's just a matter of their being overwhelmed....or the slowness of red tape on grant funds or having to specify the individual studies one by one, or perhaps they don't want to have to specify some of their research directions yet (breast cancer, autism etc.). ~Fern
     

See more popular forum discussions.

Share This Page